MARKET

CASBF

CASBF

CANSINO BIOLOGIC
OTCMKTS

Real-time Quotes | Nasdaq Last Sale

16.96
-1.54
-8.30%
Closed 13:31 01/27 EST
OPEN
16.96
PREV CLOSE
18.50
HIGH
16.96
LOW
16.96
VOLUME
150
TURNOVER
2.54K
52 WEEK HIGH
55.33
52 WEEK LOW
16.96
MARKET CAP
3.78B
P/E (TTM)
43.40
1D
5D
1M
3M
1Y
5Y
BRIEF-CanSino Plans To Buy Back Company A-Share Worth 150-300 Mln Yuan
reuters.com · 4d ago
BRIEF-JPMorgan Chase & Co's Long Position In CanSino Biologics Falls To 9.92% - HKEX Filing
reuters.com · 01/17 09:17
BRIEF-Capital Group Companies Inc's Long Position In Cansino Biologics Rises To 23.0% - HKEX Filing
reuters.com · 01/13 09:09
Latest Study Shows Encouraging Results of CanSinoBIO's Inhaled COVID-19 Vaccine as Heterologous Booster
CanSino Biologics Inc. ("CanSinoBIO") (SSE: 688185, HKEX: 06185) today announced that Preprints with The Lancet, a collaboration between the research sharing platform SSRN and The Lancet, published a clinical study on the safety and immunogenicity of CanSi...
PR Newswire · 01/11 07:15
China stocks fall as virus worries, Fed rate hike bets weigh; Hong Kong up
reuters.com · 01/11 05:15
BUZZ-Hong Kong-listed CanSino Biologics falls on share sale report
reuters.com · 01/11 02:28
CanSinoBIO Announces Approval for its MCV4 Product Menhycia™ in China
CanSino Biologics Inc. ("CanSinoBIO") (SSE: 688185, HKEX: 06185) announced that the National Medical Products Administration of China ("NMPA") granted approval for its ACYW135 Meningococcal Conjugate Vaccine (CRM197) ("MCV4", trade name: Menhycia™), making...
PR Newswire · 01/08 15:47
BRIEF-Capital Group Companies Inc's Long Position In Cansino Biologics Falls To 22.85% - Filing
reuters.com · 01/07 09:16
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CASBF. Analyze the recent business situations of CANSINO BIOLOGIC through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
66.67%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CASBF stock price target is 41.67 with a high estimate of 54.16 and a low estimate of 30.88.
High54.16
Average41.67
Low30.88
Current 16.96
EPS
Actual
Estimate
0.260.540.811.09
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 0
Institutional Holdings: 0
% Owned: 0.00%
Shares Outstanding: 222.65M
TypeInstitutionsShares
Increased
0
0
New
0
0
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
  • All
  • Financials
  • Insiders
No Data
About CASBF
CanSino Biologics Inc is a clinical-stage vaccine company in China. The Company's products include Ad5-EBOV vaccine used for Ebola virus, MCV2 and MCV4 vaccines for meningococcus, PBPV vaccine used for pneumococcal and the recombinant novel coronavirus vaccine. Its products are mainly used in meningitis, diphtheria pertussis tetanus (DPT) and pneumonia.

Webull offers kinds of Cansino Biologics Inc stock information, including OTCMKTS:CASBF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CASBF stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CASBF stock methods without spending real money on the virtual paper trading platform.